sans (78), ou avec (9) une chirurgie, 15 ont bénéficié de radiothérapie (RT) sans (13) , ou avec (2) chirurgie, 14 d'une chimiothérapie (CXT) sans (9) , ou avec (5) chirurgie. La dose médiane de RT était de 40 Gy . Le nombre médian de cycles de CXT était de 6 (2) (3) (4) (5) (6) (7) (8) . Le suivi médian était de 41 mois 6-242).
Results
The ove ra li response rate at the end of treatment was 91 % (CR 7 4%, PR 17% ).
Local recurrence or progression was observed in 12 (10%) patients and systemic recurrence in 17 (15% Almost 90% of PBL patients present with diffuse large B-cell lymphoma histological subtype, which may have a better prognosis than that of the less common T-cell lymphoma subtype [7] [8] [9] . The most commonly affected parts of the skeleton are Local radiotherapy (RT) was established as the standard treatment in the 1960's with a local relapse rate of around 10-20%, but with a distant relapse rate of about 50% and a 5-year survival rate ranging between 55-65% [11] [12] [13] . The 5-year survival rate has been improved to about 70-90% with the addition of chemoradiotherapy (CXRT) in early stage disease [11, [14] [15] [16] [17] .
Cai.6
The role of RT was recently challenged [18, 19] http//www.rarecancer.net) study was to collect substantial information from a large number of patients to more properly define the disease profile, therapeutic approach, outcome and prognostic factors of this disease.
PATIENTS AND METHODS

Patients
We Ali pathology reports were reviewed and "translated" into the WHO classification.
Cai.7
The work-up of individual patients included medical history, physical examination, Patients were treated according to each hospital's local policy. The modality of treatment included chemotherapy, RT, surgical resection or a combination of these.
Most patients had a biopsy only (1 OO), however, 16 underwent surgery: 13 had some form of local excision or curettage, 2 had a laminectomy with partial excision, and 1 had a total hip replacement.
Response was evaluated according to lymphoma-adapted RECIST [22, 23] (Response Evaluation Criteria in Solid Tumors). Early and late treatment toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) V3.0 [24] .
Statistical methods
Overall survival (OS) was calculated from the date of diagnosis to the date of last Cai.8 follow-up or death from any cause. Lymphoma-specific survival (LSS) was calculated from the date of diagnosis to the date of lymphoma-related death. Local control (LC) was calculated from the date of diagnosis to the date of local recurrence. Survival curves were constructed using the Kaplan-Meier method, differences were considered significant if the P value wa §.05 (two tailed Log-rank test). Multivariate analysis (Cox model) was used to determine the independent prognostic factors. Ali prognostic factors identified in the univariate analyses with P value < 0.20 were included in the multivariate analyses.
RESULTS
Patient and treatment characteristics are presented in Table 1 .
Median age was 51 years (range 17-93 years), and there were 69 males (59%) and 47 females (41%).
Majority of patients (75%) received combined CXRT. Treatment sequences were chemotherapy followed by radiotherapy (CT-RT) in 64%, radiotherapy followed by chemotherapy (RT-CT) in 8%, and concomitant CXRT in 3%. Eighty-eight percent received chemotherapy (CXT) in combination or alone. Of these, 68% were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy, and 32% with rituximab plus CHOP (R-CHOP) chemotherapy.
Response to treatment was evaluated in ail patients. After initial therapy, 74%
patients had a complete remission (CR), 20% partial remission (PR), 1 % stable Cai.9 disease (SD), and 5% progressive disease (PD). One patient who experienced progressive disease, died during salvage treatment. Among patients achieving a CR, 81 % were treated with combined CXRT, 10% with RT alone, and 9% with CXT alone.
The 5-and 10-year LC probability was 92% (95% Cl: 86-98) and 80% (95% Cl:
68-92), respectively. Local failure was observed in 10% of the patients. Of the 7 4%
patients with CR, 6% had a local relapse, whereas of the 20% of patients who were in PR, 30% presented a further local progression (P=0.008).
Of the patients who received an RT dose of less than 40 Gy, 12% recurred locally, versus 8% of those receiving more than 40 Gy (P=0.75). ln the patients with local failure, 50% occurred within the planning target volume and 50% outside . Table 2) .
After multivariate analysis, the remaining independent prognostic factors for OS and LSS were IPI score < 2, RT dose > 40 Gy, CR, and administration of chemotherapy. For LC, CR at completion of treatment remained the only independent prognostic factor ( Table 3) . 
DISCUSSION
To our knowledge, the current study from 13 institutions of the RCN is the second largest report on early stage PBL. Cai.11 lt has demonstrated relatively similar patient characteristics compared to other published series. A male predominance (male to female: 1.43:1) was found, and median age was 51 years, compared to 30-60 years in other series. Pain was the most common presenting symptom, followed by a mass or swelling. The most common sites of pathological fracture were usually located in the long bones, similar to other reports [7, 25] . Like in other reports [26] , most of our patients presented with Stage IE (ratio between Stage IE and llE: 4:1 ).
The overall outcome of patients in this study (5-year OS of 76%, LSS of 78%) was similar to that found in the literature (5-year OS ranging between 70-90%) [11, [14] [15] [16] [17] 27] .
Univariate analysis for OS in our study revealed that younger age (< 50 years) predicted a better outcome, as reported in other series [11, 26] . Normal LDH level was considered to be a favorable prognostic factor in the report of Beal et al [11 ] , but in our series we could not confirm this observation. Patients with IPI scores 0-1 had a markedly better outcome compared to those with an IPI score 2-4, as previously found by Ramadan et al [4] , but not by Alencar et al [27] . ln contrast to the study of Ostrowski et al [13] and Horsman et al [26] , high grade histology was slightly beneficial compared to low grade histology for OS and LSS. Previously published papers utilizing SEER database analysis [28] RT was established in the 1960's as the treatment of choice with a high local control rate and overall cure rates ranging from 44-63% [11, 27] . However, the role of RT alone was challenged over recent years, due to the 50% systemic progression rate [11, 30] . Barbieri et al reported that an RT dose of 40 Gy with a limited RT volume in combination with CXT seemed to be adequate for local control [17] . Our study addressed the issue of RT dose and volume. Radiation of the entire bone did not yield a superior outcome compared to partial bone radiation (62% vs.
70%, P=0.88). However, both univariate and multivariate analyse showed that RT dose > 40 Gy was associated with a significantly better 5-year OS and LSS than ::; 40Gy (95% vs. 66%, P=0.0054, and 95% vs. 69%, respectively) and a non-significant trend towards a better local control (96% vs. 89%, P=0.32).
CXRT already demonstrated its superiority compared to single therapeutic approaches with 5-year OS between 60-90% in recent studies [11, 16, [31] [32] [33] .
lnterestingly, Alencar et al [27] recently reported no benefit with CXRT. Although there is no consensus regarding the optimal timing between either RT or chemotherapy, chemotherapy followed by RT was suggested to be the standard Cai.13 approach [34] .
With the advent of highly effective chemotherapy, the raie of RT has been questioned by some authors. ln advanced-stage disease, Ramadan et al found that patients who received chemotherapy and RT had a worse outcome compared to those who received chemotherapy alone [4] . ln the SWOG 8736 study update which was on non-PBL lymphoma, there was no difference between CXRT and chemotherapy alone [18, 19] . Similar results were reported in some studies [11, 35, 36] , and also in a report on children [37] . Rituximab is now used in association with CHOP or a CHOP-like regimen in the treatment of lymphoma, and studies have demonstrated its positive impact on survival [38] . ln our series, the proportion of patients treated with R-CHOP was lower (3:7) than with CHOP alone, and we could not find any significant differences in survival between the two regimens.
Acute side effects were moderate. Leukopenia was the most common early toxicity following chemotherapy. The only reported late toxicity cases involved a limited occurrence of osteonecrosis.
ln conclusion, early stage PBL has a fairly good prognosis. Local contrai is excellent, and systemic failure occurs infrequently. Young age(< 50) and a good IPI score(< 2) were positive prognostic factors at diagnosis. The raie of chemotherapy is central in the treatment of PBL. Chemotherapy followed by RT is superior for OS and LSS to a sequence of radiotherapy followed by chemotherapy. Although chemotherapy was superior to radiotherapy alone, radiotherapy still plays a raie in local contrai. An RT dose of more than 40 Gy, and more than 6 chemotherapy Cai.14 cycles are associated with a better outcome. Although our results need to be interpreted with caution because of a relatively limited follow up (41 months) and its retrospective nature, we feel that our findings are important, especially because it is unlikely that a prospective study will be done, given how rare this cancer is.
Figure legends improved LC compared with those without CR. 
